Cargando…

Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC)

Immune checkpoint inhibition (ICI) of the PD-1/PD-L1 axis shows durable responses in a subset of patients with metastatic urothelial carcinoma (UC). However, PD-L1 expression in tumor biopsies does not necessarily correlate with response to PD-1/PD-L1 inhibitors. Thus, a reliable predictive biomarke...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bergmann, Sonja, Coym, Anja, Ott, Leonie, Soave, Armin, Rink, Michael, Janning, Melanie, Stoupiec, Malgorzata, Coith, Cornelia, Peine, Sven, von Amsberg, Gunhild, Pantel, Klaus, Riethdorf, Sabine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199812/ https://www.ncbi.nlm.nih.gov/pubmed/32391189 http://dx.doi.org/10.1080/2162402X.2020.1738798

Ejemplares similares

The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer
por: Riethdorf, Sabine, et al.
Publicado: (2017)

Detection of Androgen Receptor Variant 7 (ARV7) mRNA Levels in EpCAM-Enriched CTC Fractions for Monitoring Response to Androgen Targeting Therapies in Prostate Cancer
por: Hille, Claudia, et al.
Publicado: (2019)

The Impact of Circulating Tumor Cells on Venous Thromboembolism and Cardiovascular Events in Bladder Cancer Patients Treated with Radical Cystectomy
por: Rink, Michael, et al.
Publicado: (2020)

The current role of circulating biomarkers in non-muscle invasive bladder cancer
por: Rink, Michael, et al.
Publicado: (2019)

Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study
por: Soave, Armin, et al.
Publicado: (2017)

First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial
por: Paschold, Lisa, et al.
Publicado: (2023)

Influence of Androgens on Immunity to Self and Foreign: Effects on Immunity and Cancer
por: Ben-Batalla, Isabel, et al.
Publicado: (2020)

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer
por: Roßwag, Sven, et al.
Publicado: (2021)

CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis
por: Loreth, Desiree, et al.
Publicado: (2021)

Immunotherapy in Advanced Prostate Cancer—Light at the End of the Tunnel?
por: von Amsberg, Gunhild, et al.
Publicado: (2022)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
por: Janning, Melanie, et al.
Publicado: (2019)

Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression
por: Bednarz-Knoll, Natalia, et al.
Publicado: (2015)

Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan
por: Fontes, Mariane S, et al.
Publicado: (2022)

Circulating tumor cells (CTCs) and hTERT gene expression in CTCs for radiotherapy effect with lung cancer
por: Xu, Ying, et al.
Publicado: (2023)

Ethische Herausforderungen in der Onkologie
por: Woellert, Katharina, et al.
Publicado: (2022)

Liquid biopsies in bladder cancer—did we find the Holy Grail for biomarker analyses?
por: Rink, Michael, et al.
Publicado: (2016)

Detection and Characterization of Estrogen Receptor α Expression of Circulating Tumor Cells as a Prognostic Marker
por: Ningsi, Retno, et al.
Publicado: (2022)

Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay
por: Belloum, Yassine, et al.
Publicado: (2020)

Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCs
por: Allen, Joshua E., et al.
Publicado: (2013)

Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients
por: Riethdorf, Sabine, et al.
Publicado: (2009)

ERBB signaling in CTCs of ovarian cancer and glioblastoma
por: Geethadevi, Anjali, et al.
Publicado: (2017)

CTCs 2020: Great Expectations or Unreasonable Dreams
por: Rossi, Elisabetta, et al.
Publicado: (2019)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)

Erdafitinib treatment in Brazilian patients with metastatic urothelial carcinoma (mUC): real-world evidence from an Expanded Access Program
por: Monteiro, Fernando Sabino M., et al.
Publicado: (2021)

Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study)
por: Bilen, Mehmet A, et al.
Publicado: (2023)

EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients
por: Scharpenseel, Heather, et al.
Publicado: (2019)

Evaluation of α-tubulin, detyrosinated α-tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements
por: Kallergi, G., et al.
Publicado: (2018)

Implementing Cisco UCS solutions
por: Ahmed, Farhan, et al.
Publicado: (2013)

High Density UC Properties
por: Luigi B. TecchioLaboratori Nazionali di Legnaro
Publicado: (05/1)

UC Updatable Databases and Applications
por: Damodaran, Aditya, et al.
Publicado: (2020)

EMT, CTCs and CSCs in tumor relapse and drug-resistance
por: Mitra, Abhisek, et al.
Publicado: (2015)

CTCs Expression Profiling for Advanced Breast Cancer Monitoring
por: Pereira-Veiga, Thais, et al.
Publicado: (2019)

Potential Use of CTCs as Biomarkers in Renal Cancer Patients
por: Bialek, Joanna, et al.
Publicado: (2022)

Combinatorial Power of cfDNA, CTCs and EVs in Oncology
por: Keup, Corinna, et al.
Publicado: (2022)

Ex vivo expansion of circulating tumour cells (CTCs)
por: Mohamed, Bashir M., et al.
Publicado: (2023)

Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions
por: Schochter, Fabienne, et al.
Publicado: (2019)

Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

Bosutinib in the management of chronic myelogenous leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy
por: Houédé, N., et al.
Publicado: (2016)

Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder
por: Vetterlein, Malte W., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1k8khp5qtiaf75jd1r8qtk6c9t